Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment

Thrombosis Research

Volumn 148, Issue , 2016, Pages 107-110

  McGrail, Rie ^a   Revsholm, Jesper ^a   Nissen, Peter H ^a   Grove, Erik L ^a,b   Hvas, Anne Mette ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Anticoagulants; Apixaban; Dabigatran; DOAC; Drug monitoring; Rivaroxaban

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ASSAY; BLOOD SAMPLING; BLOOD STORAGE; CONTROLLED STUDY; DRUG STABILITY; FREEZE THAWING; HEMOSTASIS; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEADY STATE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; DRUG MONITORING; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DABIGATRAN; DRUG MONITORING; DRUG STABILITY; HUMANS; PYRAZOLES; PYRIDONES; RIVAROXABAN;

EID: 84994644478     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.10.023     Document Type: Letter

References (9)

1. [1] Wang, Y., Bajorek, B., New oral anticoagulants in practice: pharmacological and practical considerations. Am. J. Cardiovasc. Drugs 14 (2014), 175–189.
2. [2] Garcia, D., Barrett, Y.C., Ramacciotti, E., Weitz, J.I., Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J. Thromb. Haemost. 11 (2013), 245–252.
3. [3] Breuer, G., Weiss, D.R., Ringwald, J., ‘New’ direct oral anticoagulants in the perioperative setting. Curr. Opin. Anaesthesiol. 27 (2014), 409–419.
4. [4] Schmitz, E.M., Boonen, K., van den Heuvel, D.J., van Dongen, J.L., Schellings, M.W., Emmen, J.M., van der Graaf, F., Brunsveld, L., van de Kerkhof, D., Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J. Thromb. Haemost. 12 (2014), 1636–1646.
5. [5] Douxfils, J., Dogne, J.M., Mullier, F., Chatelain, B., Ronquist-Nii, Y., Malmstrom, R.E., Hjemdahl, P., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb. Haemost. 110 (2013), 543–549.
6. [6] Skeppholm, M., Al-Aieshy, F., Berndtsson, M., Al-Khalili, F., Ronquist-Nii, Y., Soderblom, L., Ostlund, A.Y., Pohanka, A., Antovic, J., Malmstrom, R.E., Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb. Res. 136 (2015), 148–153.
7. [7] Kemkes-Matthes, B., Fischer, R., Peetz, D., Influence of 8 and 24-h storage of whole blood at ambient temperature on prothrombin time, activated partial thromboplastin time, fibrinogen, thrombin time, antithrombin and D-dimer. Blood Coagul. Fibrinolysis 22 (2011), 215–220.
8. [8] Francart, S.J., Hawes, E.M., Deal, A.M., Adcock, D.M., Gosselin, R., Jeanneret, C., Friedman, K.D., Moll, S., Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb. Haemost. 111 (2014), 1133–1140.
9. [9] Hawes, E.M., Deal, A.M., Funk-Adcock, D., Gosselin, R., Jeanneret, C., Cook, A.M., Taylor, J.M., Whinna, H.C., Winkler, A.M., Moll, S., Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J. Thromb. Haemost. 11 (2013), 1493–1502.